Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
239.10
+6.27 (2.69%)
Oct 15, 2026, 12:17 PM EDT - Market open
Biogen Stock Forecast
Stock Price Forecast
According to 36 analysts polled by S&P Global, Biogen stock has a consensus rating of "Buy" and an average price target of $243.98. The average 1-year stock price forecast is 2.04% higher than the current stock price, while the lowest is $175 (-26.81%) and the highest is $300 (+25.47%).
Price Target: $243.98 (+2.04%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Biogen stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 18 | 20 | 20 | 19 | 20 |
| Buy | 2 | 3 | 3 | 3 | 3 | 4 |
| Hold | 15 | 14 | 12 | 11 | 12 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 36 | 36 | 36 | 35 | 35 | 36 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $250 | Buy | Maintains | $250 | +4.56% | Oct 15, 2026 |
| BMO Capital | BMO Capital | Hold Maintains $208 → $220 | Hold | Maintains | $208 → $220 | -7.99% | Oct 12, 2026 |
| Citi | Citi | Hold Maintains $215 | Hold | Maintains | $215 | -10.08% | Oct 12, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $245 | Buy | Reiterates | $245 | +2.47% | Oct 12, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Upgrades $210 → $300 | Buy | Upgrades | $210 → $300 | +25.47% | Oct 12, 2026 |
Financial Forecast
Revenue This Year
10.44B
from 9.89B
Increased by 5.54%
Revenue Next Year
10.64B
from 10.44B
Increased by 1.91%
EPS This Year
12.53
from 15.28
Decreased by -18.01%
EPS Next Year
16.52
from 12.53
Increased by 31.87%
EPS and Forward PE are based on non-GAAP adjusted numbers.